Updated on 4 November 2013
Mr Alex Chang has had a 24-year-long career in the global pharmaceutical industry holding positions in Singapore, Shanghai, Beijing, Guangzhou, Taipei, Hong Kong and the US
Singapore: Switzerland's specialty biopharmaceutical group, Ferring Pharmaceuticals has appointed Mr Alex Chang as the Senior Vice President of the company's Asia Pacific region. The appointment is effective from November 1, 2013.
The company said that Mr Chang will report directly to Mr Michel Pettigrew, President of the Executive Board and COO, Ferring Group.
"As Senior Vice President, Asia Pacific, Mr Chang will be responsible for continued development and performance of Ferring businesses in China, Japan, South Korea, South East Asia, India, Australia, New Zealand and South Africa," it said.
With a career spanning over 24 years in the global pharmaceutical industry, Mr Alex Chang has held positions in Singapore, Shanghai, Beijing, Guangzhou, Taipei, Hong Kong and the United States. As Head of the Asia Cluster at Novartis since 2011, Mr Chang led nine country operations and 2,700 employees. Prior to Novartis, he held several senior management positions for Janssen in China and Taiwan and for Bristol-Myers Squibb in China and the USA.
"We are happy to welcome Alex to the Ferring team. We are confident that his deep industry knowledge and broad regional experience will contribute to Ferring growth in the Asia-Pacific region," Mr Michel Pettigrew, President of the Executive Board and COO, Ferring Group said in the company's statement.
The Switzerland headquarted research-driven, specialty biopharmaceutical group identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. The company has its own operating subsidiaries in 55 countries and markets its products in more than 100 countries.